MX2012007933A - Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. - Google Patents

Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.

Info

Publication number
MX2012007933A
MX2012007933A MX2012007933A MX2012007933A MX2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A MX 2012007933 A MX2012007933 A MX 2012007933A
Authority
MX
Mexico
Prior art keywords
methods
topical transdermal
transdermal dexmedetomidine
dexmedetomidine compositions
compositions
Prior art date
Application number
MX2012007933A
Other languages
English (en)
Spanish (es)
Inventor
Geraldine A Henwood
Randall J Mack
Christopher T Sharr
John J Koleng Jr
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of MX2012007933A publication Critical patent/MX2012007933A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012007933A 2010-01-08 2011-01-07 Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. MX2012007933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29344010P 2010-01-08 2010-01-08
PCT/US2011/020462 WO2011085162A2 (en) 2010-01-08 2011-01-07 Topical transdermal dexmedetomidine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2012007933A true MX2012007933A (es) 2012-08-15

Family

ID=44306157

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007933A MX2012007933A (es) 2010-01-08 2011-01-07 Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.

Country Status (10)

Country Link
US (1) US20130072532A1 (enExample)
EP (1) EP2521544A4 (enExample)
JP (1) JP2013516482A (enExample)
CN (1) CN102753169A (enExample)
AU (1) AU2011204315A1 (enExample)
CA (1) CA2786598A1 (enExample)
MX (1) MX2012007933A (enExample)
NZ (2) NZ601195A (enExample)
RU (1) RU2012133969A (enExample)
WO (1) WO2011085162A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470516A (zh) 2011-12-11 2015-03-25 瑞克欧制药有限公司 鼻内右美托咪定组合物和其使用方法
AU2014262960A1 (en) * 2013-05-06 2015-11-26 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
WO2015054063A1 (en) * 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
TWI704933B (zh) * 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
KR20180095733A (ko) * 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20210113439A (ko) * 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN107929234B (zh) * 2017-12-25 2021-07-23 温州医科大学附属第一医院 一种应用于烧伤创面修复的外用制剂膏体
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN113577556A (zh) * 2021-08-01 2021-11-02 武汉左点科技有限公司 一种用于阴道康复治疗的生物反馈电刺激方法及装置
WO2024037545A1 (zh) * 2022-08-17 2024-02-22 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Also Published As

Publication number Publication date
EP2521544A2 (en) 2012-11-14
AU2011204315A1 (en) 2012-08-02
CN102753169A (zh) 2012-10-24
EP2521544A4 (en) 2013-08-21
NZ601195A (en) 2015-02-27
CA2786598A1 (en) 2011-07-14
US20130072532A1 (en) 2013-03-21
WO2011085162A3 (en) 2011-11-17
RU2012133969A (ru) 2014-02-20
NZ703808A (en) 2016-01-29
JP2013516482A (ja) 2013-05-13
WO2011085162A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
GB201111485D0 (en) Drug composition and its use in therapy
SG10201700125VA (en) Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
EP2190408A4 (en) ANALGETIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHOD FOR THE TREATMENT, PREVENTION OR TREATMENT OF PAIN AND IGNITION
EP3054931A4 (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
IL251543B (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
EP2897621A4 (en) COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES
PH12012501389A1 (en) Hedgehog inhibitors
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EP3449917A3 (en) Tapentadol for preventing chronification of pain
DK2155179T3 (da) Axomadol til smertebehandling arthrose
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
HK1177894A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal